Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Pouch of convalescent plasma with a hospital environment visible in the background © NHSBT

However, the results followed a slightly different pattern for the 126 patients who had immune system deficiencies. This group of patients appeared to do slightly better with the convalescent plasma treatment, compared to the standard treatment, but the number of patients were too small to make a definitive statement.

The study, published in the journal JAMA, is part of the ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP), a large international trial with over 300 trial centres in 21 countries.

Read the full story on the Radcliffe Department of Medicine website.

Similar stories

Wearing face coverings protected wearers from COVID-19 infection – large scale study

People who wore face coverings or masks outside of the home, and were more exposed to infection due to their circumstances, had ‘significantly’ lower rates of COVID-19 infection, according to research published in BMJ Open today, led by Oxford’s Leverhulme Centre for Demographic Science.

Oxford-led team given £6.6m to map uncharted networks in the progression of Parkinson’s

A major new $9 million (£6.6 million) project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. It is the only UK-led ASAP project this year, and the first ever to be led by Oxford.

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.